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KEY POINTS
 The two most widely used forms of allergen immunotherapy (AIT) for treatment of
aeroallergen-induced allergic diseases are the subcutaneous and the sublingual AIT. Sub-
stantial developments in AIT took place in the last decade to overcome problems in stan-
dardization, efficacy, safety, long duration of treatment, and costs.
 However, accurate descriptions of AIT-responsive disease endotypes with well-defined
biomarkers continues to be an unmet need.
 AIT uses general mechanisms of immune tolerance to allergens with changes in allergen-
specific memory T- and B-cell responses, regulation of allergen-specific IgE and IgG pro-
duction, and modification of mast cell and basophil activation thresholds or dendritic cell
phenotypes.
 The main highlights of recent years are advances in the understanding of innate lymphoid
cells (ILC) including involvement of type 2 ILCs in development of allergic airway inflam-
mation, and contribution of type 3 ILCs to Breg cell–mediated immune tolerance.
 There is a need for further investigation of AIT mechanisms and biomarkers to identify the
best candidates for AIT, the long-term responders.
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INTRODUCTION
The two biggest success stories in allergy treatment are topical glucocorticosteroids
and allergen immunotherapy (AIT). Glucocorticosteroids, the principal pharmaceuti-
cals of allergy treatment, efficiently treat inflammation without curing the disease.
AIT is the only therapeutic approach exerting profound effect on basic mechanisms
of the disease, and is able to modify the disease course. Although glucocorticosteroid
treatment also exerts some tolerance-inducing effects via its regulatory T (Treg) cell–
inducing capacity,1,2 AIT is considered to be the only treatment option with the
promise of healing and induction of long-lasting tolerance, persisting even after
discontinuation of therapy. Glucocorticosteroid treatment is efficient, but not effective
enough, whereas AIT is effective but not efficient enough.3 Consequently, aiming for
the ideal therapy to overcome the global burden of allergy, a disease-modifying treat-
ment, such as AIT, is the best choice. Substantial progress has been made in the last
decade to overcome problems in standardization, efficacy, safety, long treatment
duration, patient adherence, and costs of AIT, and as a result, new guidelines have
been implemented.4–12 Here, we summarize some major advancements of the last
years in the understanding of AIT mechanisms. This review is focused on recent find-
ings and better understanding of the mechanisms of subcutaneous and sublingual
aeroallergen immunotherapy (SCIT and SLIT, respectively).
Difficulties in the management of allergic disease originate from its heterogeneity in
patient population. Phenotyping allergic diseases helps identify clinical and morpho-
logic characteristics and unique responses to treatment. However, phenotypes do
not seem to be directly linked to molecular mechanisms of the disease. Endotypes
of allergy and asthma describe certain mechanisms of the subgroups of the diseases,
such as metabolic, inflammatory, immunologic, and remodeling pathways involved in
the pathogenesis.13–15 The relationship of the endotypes to AIT responsiveness is un-
clear thus far. It is hoped that detailed description of allergy endotypes and identifica-
tion of their biomarkers will enable more successful, endotype-driven AIT strategies in
the future. In particular, AIT-responsive endotypes should be identified and bio-
markers of these endotypes should be discovered and become available at the point
of care. These biomarkers should define AIT-responsive patients as early as possible.
ROLE OF VARIOUS T CELLS IN ALLERGEN TOLERANCE AND IMMUNOTHERAPY
Regulatory T Cells
Immune tolerance to allergens implies changes in memory-type allergen-specific T-
and B-cell responses, regulation of allergen-specific IgE and IgG production, and
modification of mast cell and basophil activation thresholds or dendritic cell (DC) phe-
notypes (Fig. 1). Different levels of evidence from direct in vivo data and in vitro exper-
iments demonstrate the role of allergen-specific Treg cells in allergen tolerance in
humans.
Strong in vivo evidence has been obtained by investigation of biopsies of
affected tissue and skin late-phase responses. A decrease in T helper cell type 2
(TH2) and eosinophils and a parallel increase in Treg cells and their cytokines in
the tissue is observed after AIT.16 In the last two decades, the pivotal role of Treg
cells in induction and maintenance of immune tolerance has been demonstrated.
This is further supported by the fact that adoptive transfer of Treg cells, depending
on the timing of administration, can play a role in the prevention or treatment of
several T-cell-mediated diseases, including allergic airway inflammation and hyper-
responsiveness,17 a large spectrum of autoimmune diseases (eg, diabetes mellitus,
experimental autoimmune encephalomyelitis, inflammatory bowel disease,
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systemic lupus erythematosus, rheumatoid arthritis), and graft-versus-host disease
after allogeneic hematopoietic stem cell transplantation; and inhibit rejection of the
graft after allogeneic solid organ transplantation in mouse models of these condi-
tions. The human application of adoptive Treg cell transfer therapy is currently being
pursued in many studies.18,19 In the clinical setting, SCIT and SLIT have been
shown to induce allergen-specific Treg cells in humans. Peripheral T-cell tolerance
is characterized mainly by generation of allergen-specific Treg cells and decrease of
TH2 cells.
20–24
Direct ex vivo analysis of human peripheral blood cells without any in vitro culture
also provided evidence to support the role of Treg cells in maintenance of immune
tolerance. Samples were collected from patients allergic to bee venom during
AIT and from healthy beekeepers, who were not allergic to bee venom, on acquiring
natural tolerance to high-dose allergen exposure during beekeeping season.
Allergen-specific CD41 T cells, identified using major histocompatibility complex
class II tetramers, and interleukin (IL)-4, interferon (IFN)- g, and IL-10 cytokine-
secreting cells have been analyzed in these studies. These data demonstrate that
allergen-specific Treg cells increase and allergen-specific and nonspecific TH2 cells
decrease in parallel with the induction of natural or clinical immune tolerance in bee-
keepers during beekeeping season and AIT-treated patients with allergy, respec-
tively.24,25 AIT also promotes allergen-specific IL-22 and IFN-g producing TH
cells.24,26 It is now well understood that allergen-specific Treg cells and allergen-
specific and nonspecific effector T cells contain several distinct phenotypic compart-
ments.27 AIT involves upregulation of the activated Treg and downregulation of
allergen-specific immunoglobulin-like transcript 3 (ILT3)-expressing, dysfunctional
Treg cells.
24 ILT31 Treg cells were identified as dysfunctional Treg cells, because they
have impaired suppressive potency and they are unable to control the maturation of
TH2-inducing DCs.
28
Additional evidence has been obtained from cell cultures. IL-10 and transforming
growth factor-b are produced by antigen-specific Treg cells. Treg cells from donors
Fig. 1. Overview of the basic mechanisms of allergen immunotherapy. Regulatory T and B
cells play a central role in the suppression of allergic inflammation, mainly by means of their
interleukin-10 and transforming growth factor-b production. Green arrows indicate induc-
tion; red arrows indicate inhibition. Breg, regulatory B cell; IL, interleukin; TGF, transforming
growth factor.
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with atopy have a reduced capability to suppress T-cell proliferation. Immune toler-
ance induced by SLIT is associated with an increase in Treg cell numbers; elevated
IL-10 production in sublingual FOXP3-expressing Treg cells; and elevated allergen-
specific IgG4, IgA levels and serum blocking activity for IgE-facilitated allergen binding
(IgE-FAB) to B cells.23,29,30 IL-10-producing Treg cells suppress TH2-type immune
response and IL-17-producing TH cells.
31,32
It has been recently demonstrated that a significant increase in the numbers of
allergen-specific FOXP31Helios1CD251CD127– Treg cells took place at the end
of up-dosing phase (10 weeks), which only slightly decreased at the end of the
maintenance phase (3 years) of house dust mite (HDM) SCIT.24 In contrast, ILT31
dysfunctional Treg cells
28 decreased substantially after 3 years of SCIT.24 Addition-
ally, IL-101 allergen-specific Treg cells are still present at high frequency at the end
of SCIT. Increased number of FOXP31Helios1 and IL-101 Treg cell and
decreased ILT31 Treg cell responses correlated with improved allergic symptoms.
These data further confirm that the induction of allergen-specific functional Treg
cells is one of the key events of AIT.24 In all of these mechanisms, the H2 receptor
plays an important role. It has been shown that it can suppress DCs, T cells,
natural killer T cells, and basophils. This results in antagonizing the proallergic ef-
fects of histamine via the H1 receptor.
33–35 Histamine signaling is a newly deter-
mined link between microbiome and immune tolerance. It has been recently
shown that histamine-secreting commensal bacteria exist in human gut and are
linked to severity of asthma36 and have pleiotropic effects on tolerance in the
lungs.37,38
Taken together, the critical role for allergen-specific Treg cell–mediated immune
tolerance in successful AIT is well established. However, this is not the only mecha-
nism operational in the AIT-induced tolerance.
The equally important immunologic phenomenon that warrants the favorable
clinical outcome of AIT is the eradication of allergen-specific TH2 cells (Fig. 2).
It has been recently demonstrated that there are subsets of allergen-specific TH2
cells, such as CD27–CD45RB–CRTH21CD49d1CD1611 TH2 memory cells,
CRTH21CCR41CD27–CD41 TH2 cells,
32 or ST21CD45RO1CD41 cells,39 of special
importance in the pathogenesis of allergic diseases. These so-called TH2A cells or
pathogenic TH2 cells are specifically targeted during AIT, and their eradication is indic-
ative of favorable clinical response.3,39,40 These cells are characterized by high
Fig. 2. Direction of change in some important T-cell subsets in response to AIT. Allergen-
specific pathogenic T cells decrease and regulatory T cells increase during a successful AIT.
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expression of IL17RB (gene encoding IL-25 receptor), IL1RL1 (gene encoding ST2, a
receptor for IL-33), and CRLF2 (gene encoding TSLP receptor), and they highly ex-
press IL13 and IL5 genes.40,41
Interleukin-35
IL-35 is a newly identified inhibitory cytokine produced by Treg cells and is essential for
their immunosuppressive function.42 IL-35-inducible regulatory T (iTR35) cell is a newly
recognized subset of induced Treg cells with IL-35
1CD41CD251FOXP3– phenotype
and potent immune regulatory properties.43 The role of IL-35 and IL-35-producing
iTR35 cells in SLIT has recently been described (see Fig. 2). Proliferation and cytokine
production of allergen-specific TH2 effector cells, IL-25- or IL-33-induced IL-5 and
IL-13 production of innate lymphoid cells (ILC) 2 cells, and CD40L-, IL-4-, and IL-
21-mediated IgE production of B cells can all be inhibited by IL-35, whereas the pro-
duction of IFN-g and IL-10 is induced by this cytokine. Moreover, iTR35 cells reduce
memory T-cell proliferation and TH2 cytokine production in an IL-10- and IL-35-
dependent manner. Of note, the number of iTR35 cells and allergen-induced IL-35 pro-
duction is higher in the peripheral blood of patients with allergic rhinitis after successful
SLIT than in the blood of untreated patients, and similar to that of healthy control sub-
jects. Both the percentage and the IL-35-producing capacity of the iTR35 cells
inversely correlate with rhinitis symptom score.44 Taken together, IL-35 and its source
(iTR35 cell) may represent a new target for biomarker development and for future
therapies.45
Follicular Helper T Cells
Increasing evidence indicates that the regulation of follicular helper T (TFH) cells is also
of great importance in the success of AIT (see Fig. 2). Circulating TFH cells are divided
into subgroups corresponding to TH1, TH2, and TH17 helper cells. IgE antibody pro-
duction by B cells is supported by type 2 TFH (TFH2) cells.
46 TFH2 cell numbers are
increased in the peripheral blood of patients with allergic rhinitis, and are able to
induce IgE production on an IL-4-dependent manner. Moreover, allergen-specific
IgE levels correlate only with allergen-specific TFH2 cell frequencies, but not with non-
follicular TH2 cells frequencies in patients allergic to HDM. The numbers of TFH2 cells
reduced more sharply than TH2 cells in response to AIT. Of note, the combined symp-
tom and medication score improvement in response to SCIT correlated only with the
percent reduction of allergen-specific TFH2 cell numbers, and not with that of TH2
cells.47 TFH activities are modulated by follicular Treg (TFR) cells
48 and by regulatory
B (Breg) cells.
49 TFR cells were first described in human tonsils and differentiate from
natural Treg cells.
50 TFR cell frequencies are decreased in tonsils of patients allergic
to HDM suffering from allergic rhinitis. Tonsillar and blood TFR cell phenotypes and
numbers correlate with each other. Circulating TFR cells of patients with allergic rhinitis
fail to suppress IgE production of B cells in vitro. Circulating TFR cell frequencies are
increased and their IgE-suppressing function is improved after AIT.51 Therefore, ther-
apeutic targeting of TFR and TFH cells and their use as a biomarker has been proposed.
INNATE LYMPHOID CELLS IN ALLERGY AND ALLERGEN IMMUNOTHERAPY
Exploration of the diversity of ILCs has substantially changed the understanding of tis-
sue inflammation and immune tolerance in the last few years.52 ILCs are developmen-
tally related to natural killer cells. Novel members of the ILC family (ILC1s, ILC2s, and
ILC3s) show similar biologic characteristics, including transcription factor expression
and cytokine production, to the key cellular elements of adaptive immune response,
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the TH cell subpopulations: TH1, TH2, and TH17/TH22, respectively.
53 The whole genome
signatures of different ILCs subpopulations and ILC heterogeneity in humans have
recently been published.54,55 Particularly, ILC2s play an important role in allergic airway
inflammation.56 They are dependent on GATA3, and they substantially contribute to IL-5
and IL-13 production in allergic airway responses.57 ILC3s are RORgt-dependent cells.
Their signature-cytokine is IL-22, an important mediator of the mucosal immune de-
fense, tissue repair, and the maintenance of epithelial barrier integrity.58
It has recently been demonstrated that seasonal increase in peripheral ILC2s is
inhibited by grass pollen extract SCIT.59 Cross-sectional studies suggest that the rela-
tive proportion of circulating ILCs is affected by AIT. The ILC2/ILC1 ratio is increased in
patients allergic to HDM suffering from allergic rhinitis60; however, it is normalized by a
successful AIT. Nonresponders show similar ILC2/ILC1 ratio to untreated patients with
allergic rhinitis.61,62
Our group demonstrated that IL-101 regulatory ILCs (ILCregs) are induced from
ILC2s by retinoic acid.63 CRTH-2 and ST2 (hallmarks of ILC2s) are downregulated
and CD25 and CTLA-4 are upregulated on ILCregs. These cells are able to suppress
T-cell and ILC2 activation. Retinoic acid–producing DCs were found to help peripheral
Treg cell differentiation.
64,65 Retinoic acid–induced regulatory DCs have a protective
effect on adoptive transfer in a mouse model of food-induced anaphylaxis.66 Consid-
ering the general role of retinoic acid in tolerance-induction, the participation of ILCregs
in the mechanisms of AIT-induced tolerance is also possible.
Moreover, we demonstrated recently that activated, CD40L-expressing ILC3s
reside on the border of the T cell–B cell areas in tonsils, and are in close contact
with B cells in vivo. Furthermore, we showed that CD40L1 ILC3s and B cells are in
a mutually beneficial relationship with each other: ILC3s induce IL-15 production in
B cells via BAFF-receptor, whereas IL-15, a potent growth factor for ILC3s, upregu-
lates CD40L expression on ILC3s. IL-15-activated CD40L1 ILC3s help B-cell survival,
proliferation and differentiation of IL-10 secreting, and functional Breg cells in a CD40L-
and BAFF-receptor-dependent manner. Moreover, ILC3-induced Breg cells domi-
nantly have CD27–IgD1IgM1CD24high CD38high CD1d1 immature transitional (itBreg)
phenotype. This mechanism contributes to the maintenance of immune tolerance
to innocuous antigens and becomes insufficient in allergic diseases.67 Tonsils are
important mucosal sites of immune tolerance,68 where generation of functional
allergen-specific Treg cells occurs. We showed that ILC3s and Breg cells colocalize
in the interfollicular regions of palatine tonsils, together with Treg cells. These data sug-
gest that there are regulatory niches in tonsils where Treg and Breg cells develop next to
each other. CD40L1 ILC3s might be involved in maintenance of immune tolerance in
tonsils through induction of functional itBreg cells. These cells can contribute to sup-
pression of T-cell responses through cell-cell contact via programmed cell death-
ligand 1 and via secreted IL-10.67 These mechanisms can also play a role in immune
tolerance induction during successful SLIT (see Fig. 1).35,69
The significant reduction in total and allergen-specific IgE after 3 month of HDM SLIT
was not affected by previous tonsillectomy; however, the mitigation of nasal symptoms
and wheeze was less pronounced in the tonsillectomy group.70 In fact, only the palatine
tonsils and/or adenoids are removed or reduced during those operations, and the lingual
tonsils remained untouched.69 These data suggest that reduction of the lymphoid tissue
mass inWaldeyer ringdoesnot impedesystemic tolerance inductionbySLIT; however, it
may delay the improvement of clinical symptoms. The small-scale study did not reveal
reasons for this dichotomy.70 Neither the cellular infiltration of the affected tissues by
TH2 cells and eosinophils, nor the local IgE levels (entopy) were examined, both of
which certainly has an impact on the symptoms and may have been perpetuated in
Komlo´si et al6
tonsillectomized patients after SLIT. Larger scale, randomized, controlled studies with
appropriate blinded design are needed to be able to appreciate the influenceof tonsillec-
tomy onAIT efficacy. In addition, it should be considered that lingual tonsil, which has the
samestructureandcellular composition aspalatine tonsils, is a large lymphoidorgan that
remains intact in tonsillectomypatients. IgE-mediatedallergywas found tobeassociated
with substantially lower risk of complicated appendicitis in a cohort of children who un-
derwent surgery for acute appendicitis.71 However, the influence of appendectomy on
development of allergy, and specifically on the response to immunotherapy, has not
been investigated thus far.
REGULATORY B CELLS AND ANTIBODY PRODUCTION IN ALLERGEN TOLERANCE
AND IMMUNOTHERAPY
Regulatory B Cells
Deficiency of IL-10-producing Breg cells leads to increased inflammation in mouse
models of autoimmunity, transplantation, and chronic infection. Absolute numbers
of Treg cells and expression levels of FOXP3 in these cells are dependent on IL-10 pro-
duction by B cells. Modulation of Treg cell frequencies in vivo is exclusively restricted to
transitional 2 marginal zone precursor Breg cells in mice.
72 Of note, itBreg cells can pre-
vent and reverse airway inflammation in allergized mice by inducing recruitment of Treg
cells to the lung.73 Adoptive transfer of itBreg cells can ameliorate allergic airway
inflammation and hyperresponsiveness in a mouse model of allergic asthma in an
IL-10-dependent manner.74 Human itBreg cells are also able to induce Treg cells
in vitro.75 The relative proportion of Breg cell subsets within B cells was found to be
reduced in patients with allergic diseases, such as allergic rhinitis76 and allergic
asthma,77 and the frequency of IL-10-producing, antigen-specific B cells increased af-
ter AIT.78,79 In vivo evidence for allergen tolerance has been demonstrated: the sup-
pressive B cells and IgG4-expressing B cells are developed from IL-10
1 BR1 cells
in human subjects after AIT.80 Supporting the role of IL-10, solely IL-10-
overexpressing B cells acquired an immunoregulatory profile comprising upregulation
of suppressor of cytokine signaling 3 (SOCS3), glycoprotein A repetitions predominant
(GARP), CD25, and programmed cell death-ligand 1.81 These cells showed a signifi-
cant reduction in levels of many proinflammatory cytokines, and augmented the pro-
duction of anti-inflammatory IL-1 receptor antagonist and vascular endothelial
growth factor. In addition, IL-10-overexpressing B cells secreted less IgE and
showed a general T-cell and DC suppression.81 Moreover, a novel mechanism of
AIT-induced specific immune tolerance is suggested by our recent data. Increased
numbers of IgA- and IgG4-expressing allergen-specific memory B cells, plasmablasts,
and IL-101 and/or IL-1RA1 Breg cells were found in the peripheral blood over a 2-year
period during successful HDM SCIT (see Fig. 1).82
Modulation of Allergen-Specific IgE and IgG Responses During Allergen
Immunotherapy
Specific IgE increases in individuals allergic to pollen during the pollen season and a
successful AIT can prevent this increase. AIT itself also induces an early increase in IgE
during the up-dosing phase, which rings out in maintenance phase in parallel with the
increase in IgA and IgG4 (see Fig. 1).
83
AIT-induced IgG may be directed against the same epitopes as IgE, resulting in
direct competition for allergen binding and a blocking effect.84 Allergen-specific IgG
antibodies can inhibit IgE-mediated basophil and mast cell activation and degranula-
tion with two different mechanisms: allergen neutralization and binding to the inhibitory
FcgRIIb. It has been demonstrated recently that although only high-affinity IgG
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antibodies can have both of these effects, low-affinity IgG antibodies are still able to
inhibit mast cell activation via FcgRIIb.85 IgG4 antibodies have several features that
may play a role in their anti-inflammatory effects. Two arms of IgG4 have the ability
to separate and repair by dynamic Fab arm exchange, which leads to bispecific anti-
bodies that are functionally monomeric.86 Furthermore, IgG4 does not fix complement
and is capable of inhibiting immune-complex formation by other isotypes.87 It is likely
the decrease in IgE/IgG4 ratio during AIT is a biomarker of skew from allergen-specific
TH2 to Treg cell and Breg cell predominance. IL-10 is a potent suppressor of total and
allergen-specific IgE, whereas it simultaneously increases IgG4 production.
21,88
The characteristic changes in the level of IgE and IgG4 during SCIT is mirrored by the
local concentrations of those immunoglobulins in nasal secretions45 and saliva.89
The results of some recent studies confirm that the IgG4-mediated inhibition of
CD23-dependent IgE-FAB,90 rather than the serum concentration of IgG4 solely, is a
valuable biomarker of the AIT clinical outcome.29,91 Other investigators evidenced
that specific IgG4 and inhibition of IgE-FAB correlates well with clinical efficacy of
AIT.92 Inhibition of IgE-FAB by nasal secretions correlates more closely with clinical
outcome than that of serum samples after SCIT.45
Regulation of Mast Cells and Basophils by Allergen Immunotherapy
Clinical desensitization starts as early as after the first injection of SCIT. This is mainly
linked to decreased mast cell and basophil degranulation, which has been demon-
strated in a mouse model.93 One of the main soluble factors released from mast cells
and basophils following allergen challenge is histamine, which mediates its effects via
histamine receptors. Immunosilencing of FcεRI-activated basophils by means of se-
lective suppression mediated by H2 receptor might be highly relevant for the early
desensitization effect, at least in venom AIT.94 Although there are individual differ-
ences and risks for developing systemic anaphylaxis, the suppression of mast cells
and basophils is further increased during the course of AIT. Early reduction in basophil
sensitivity predicts symptom relief also in grass pollen immunotherapy.95 Furthermore,
basophil expression of diamine oxidase shows a significant increase after AIT and is
suggested as a novel biomarker of AIT responsiveness.96
OTHER ASPECTS OF IMMUNOTHERAPY
It has been demonstrated in mouse model of allergic asthma in vivo and human bron-
chial epithelial cell cultures in vitro that AIT contributes to the restoration of the airway
epithelial barrier integrity by the reduction of IL-25 production. IL-25 is one of the main
inducers of endoplasmic reticulum stress and tight junction damage.97 It has been
recently shown in a 5-year clinical study that grass pollen SLIT significantly reduces
the risk of experiencing asthma symptoms and decreases the need for asthma med-
ications.98 The systematic meta-analyses of contribution of AIT in allergic asthma99
and allergic rhinoconjunctivitis100 have been recently published, supporting the previ-
ously mentioned study and confirming that AIT has positive effects on various allergic
diseases. The effects of AIT for various phenotypes and endotypes of allergic diseases
need to be further elucidated in vivo in animal models and directly in human
tissue.101,102
SUMMARY
AIT offers an efficient treatment of allergic diseases with a possibility of cure. There is
strong evidence for clinical safety and efficacy of AIT. Demonstration of allergen-
specific T- and B-cell tolerance, mediated, among others, by the immunosuppressive
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functions of IL-10, led to a major conceptual change in this area and opened a way to
bring AIT from empiricism to a treatment with solid mechanisms of action linked to im-
mune tolerance. The accurate definition of disease endotypes and a correct selection
of the responder patients with well-defined biomarkers still remain essential unmet
needs in the clinical setting. Therefore, deeper understanding of immuno-
pharmaco-metabolo-genomics of allergy and the impact of the environmental
exposure and the microbiome on it will probably help improve the AIT to accomplish
vaccination strategies that are suitable for whole population-based allergy prevention
and cure in the future.
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